EIC Transition project
Volumetric spatial transcriptomics for 3D culture-innovated drug development
Project summary
Spatial biology is transforming how we understand disease, but most existing tools are limited to 2D tissue sections or lack the resolution and scalability needed for real-world drug discovery and diagnostic applications.
With a €2 million non-dilutive grant from the European Innovation Council (EIC) Transition Program, Cubase Bio is advancing its 3D spatial transcriptomic technology from TRL 4 to TRL 6 transforming an early-stage innovation into a validated, commercial-ready prototype.
Over the course of the project, the technology will be validated across a range of 3D organoid models, with automation integrated into the workflow to improve reproducibility and throughput. The result will be ready-to-use reagent kits and software prototypes, tested in real-world conditions by early-access partner laboratories.
Project timeline
Technology development
- Developing Spatial Fuseseq protocols
- Refinements to 3D computational reconstructions
- Proof of concept drug-treated studies for intact organoids
Scaling & Automation
- Workflow automation in 384 well plates
- Software programming and system calibration
- Validation and benchmarking against manual results
Phase 03
User-ready reagent kits and software
- Software and user interface development
- Establishment of in-house production capabilities
- Reagent Kit Prototyping and QC
Phase 04
Market validation & user testing
- Finalizing business models and IP strategy
- Deployment of beta-test kits to early-access partners
- Achieve TRL 6 through successful external user-site demonstrations
Phase 05
TEAM
Malte Kühnemund
.png)
Toon Verheyen
.png)
Julian Ashby
Gabriele Girelli
.png)
Paulius Mielinis
.png)
Olivia Rudqvist
Xiaoyan Qian
Wenyu Li
Have a project in mind?
Contact us to to discuss your project.
